

**Present:**

Professor D Dodwell	Breast NSSG Representative
Dr J Dent	Colorectal NSSG Representative
Dr D Jackson	Gynae NSSG Representative
Dr R Johnson	Haematology NSSG Representative
Mr P Trueman	Health Economist (York Health Economics Consortium)
Mr G Fell (Chair)	NHS Bradford & Airedale
Mrs J Cawtheray	NHS Calderdale
Mrs S Frier	NHS Leeds
Mr D Thomson	Yorkshire Cancer Network

**Apologies**

Dr T Perren

<b>1. Welcome and Apologies</b>			
Log No	Action	Lead(s)	Deadline
1	<p>Greg Fell chaired the meeting in Sean Duffy's absence and introductions were made around the table. The group nominated Greg Fell as the group chair and David Jackson as vice chair.</p> <p>Sophie Thornborow to amend the membership list and update the YCN website.</p>	S Thornborow	22/04/2009
<b>2. Action Log from the last meeting</b>			
Log No	Action	Lead(s)	Deadline
2	The action log from the last meeting was agreed as an accurate record.	N/A	N/A
<b>3. Matters arising</b>			
Log No	Action	Lead(s)	Deadline
3	<p>David Thomson updated on actions from the last meeting; The YCN Board PCT representatives have agreed to fund Health Economist input from York Health Economics Consortium into the process for a pilot of 6 drug reviews. The YCN Board gave key messages that the impact of Health Economist input needs to be assessed and available for review at the end of the pilot.</p> <p>David Thomson informed the group that discussion at the Board suggests that the Gateway Group is expected to make recommendations to the YCN Management Board where a decision will be made regarding the commissioning of the treatment in YCN.</p> <p>Greg Fell proposed that there were three key questions that the group should ask in the process of developing this recommendation:</p> <ul style="list-style-type: none"> <li>- Does it work?</li> <li>- Is it cost effective?</li> <li>- Is it affordable?</li> </ul> <p>ToR now agreed and to be uploaded to the website.</p>	S Thornborow	29/04/2009

<b>3. Matters arising</b>			
Log No	Action	Lead(s)	Deadline
<b>4</b>	<p>Sandra Frier asked the group if it was appropriate to open the group to other Commissioning and Public Health colleagues.</p> <p>Greg Fell proposed that all 6 PCTs nominate either or Commissioning and Public Health representatives with voting rights to ensure key members attend the group.</p> <p>David Thomson to contact the PCTs for a single nomination of a Commissioner or Public Health Clinician.</p>	D Thomson	01/05/2009
<b>3.1 Post trial use of Sunitinib</b>			
Log No	Action	Lead(s)	Deadline
<b>5</b>	<p>David Thomson discussed the recommendations from the tabled paper:</p> <p>The group agreed that a decision to support the recommendation could not be made at this time and proposed that the tabled paper is circulated to the group and for a discussion via email. Responses to David Thomson by 5th May 2009.</p> <p>David Thomson to take the groups recommendation to the YCN Board meeting on 6th May 2009.</p>	PCT Representatives	05/05/2009
<b>3.2 Trastuzumab beyond progression/Lapatinib in metastatic breast cancer</b>			
Log No	Action	Lead(s)	Deadline
<b>6</b>	<p>David Thomson discussed the recommendations from the tabled paper:</p> <p>David Thomson recommended option 3.2 (b) from the paper as a way forward.</p> <p>'To not accept the use of trastuzumab beyond progression is standard practice within the YCN and review the use of trastuzumab in this setting before possibly reviewing the use of Lapatinib'</p> <p>The group agreed with David Thomson's recommendation.</p>	N/A	N/A
<b>3.3 Sorafenib in Hepatocellular carcinoma</b>			
Log No	Action	Lead(s)	Deadline
<b>7</b>	<p>David Thomson discussed the recommendations from the tabled paper:</p> <p>Option 3.1 (b) from the paper as considered as the way forward.</p> <p>' To await a NICE decision and continue funding sorafenib on an individual funding request (IFR) basis'</p>	N/A	N/A
<b>4. Process Development</b>			
<b>4.1 Health economist input</b>			
Log No	Action	Lead(s)	Deadline
<b>8</b>	<p>Paul Trueman informed the group that he had no concerns with the pilot process currently however would prefer to have an executable model submitted from a manufacturer as the group will essentially be relying on secondary analysis of published data, data submitted to NICE and SMC.</p>	N/A	N/A

<b>4. Process Development</b>			
<b>4.2 DTC feedback</b>			
Log No	Action	Lead(s)	Deadline
9	David Thomson reported feedback from DTC's on the process and the draft paperwork has been largely positive. He reminded the group that the pilots of the process would inform the evolution of the process.	N/A	N/A
<b>4.3 Updated process outline</b>			
Log No	Action	Lead(s)	Deadline
10	David Thomson discussed the Gateway Group process from the tabled paper.	N/A	N/A
<b>4.4 Criteria for topic selection</b>			
Log No	Action	Lead(s)	Deadline
11	<p>David Thomson noted that the group needed to develop criteria for selection of topics to be reviewed by the group.</p> <p>It was agreed that topics could be proposed via a number of mechanisms:</p> <ul style="list-style-type: none"> <li>- Horizon scanning by clinicians/pharmacists</li> <li>- New 'approved' regimen being flagged as requiring addition to Network list</li> </ul> <p>It was agreed that, in addition David Thomson would circulate a version of the SCG iEDM submission proforma created by Kev Smith to NSO's and organisations asking for them to propose topics. Once these were received selection criteria could be discussed and agreed by the group.</p>	D Thomson	06/05/2009
<b>5. Submissions</b>			
<b>5.1 Bevacizumab for 1st line metastatic breast cancer</b>			
Log No	Action	Lead(s)	Deadline
12	David Thomson noted that this submission was in development but that, in discussion with the clinicians it was not submitted to this meeting as it needed further work. It was proposed that this will be submitted to the next meeting on 10th June 2009.	D Thomson	10/06/2009
<b>5.2 Topotecan for relapsed small cell lung cancer</b>			
Log No	Action	Lead(s)	Deadline
13	<p>David Thomson asked the group to sign off the submission for Topotecan to be sent to the DTCs for review and to develop a budget impact model and health economic review.</p> <p>The group agreed for the submission to be reviewed and for results to be discussed at the next meeting.</p>	D Thomson	10/06/2009
<b>6. YCN approved regimen list</b>			
Log No	Action	Lead(s)	Deadline
14	David Thomson discussed the tabled papers. It was agreed that the 'trigger' for escalation of a "non-approved regimen" to the Gateway group for consideration was 3 uses locally and/or across the YCN. David Thomson to update the policy to reflect this.	D Thomson	10/06/2009

<b>7. Dates</b>			
Log No	Action	Lead(s)	Deadline
<b>15</b>	<p>The group agreed that to avoid diary inconvenience for group members the dates scheduled for the year would remain the same.</p> <p>The group discussed the Gateway Launch and agreed that to give maximum opportunity for attendance the launch would take place after the summer in September.</p> <p>David Thomson and Sophie Thornborow to circulate to agree and circulate the launch date and details.</p>	D Thomson & S Thornborow	13/05/2009

**Date of Next Meeting(s)**

Wednesday 10th June 2009 11:30am  
Board Room, Ground Floor, Trust HQ, St James's University Hospital

Wednesday 5th August 2009 2:00pm  
Committee Room 1, Trust HQ, Ground Floor, St James's University Hospital

Wednesday 30th September 2009 2:00pm  
Committee Room 1, Trust HQ, Ground Floor, St James's University Hospital

Wednesday 25th November 2009 2:00pm  
Committee Room 1, Trust HQ, Ground Floor, St James's University Hospital

Wednesday 20th January 2010 2:00pm  
Committee Room 1, Trust HQ, Ground Floor, St James's University Hospital